XML 21 R10.htm IDEA: XBRL DOCUMENT
v3.20.2

EARNINGS PER SHARE | 6 Months Ended
--- | ---
Jun. 30, 2020
Earnings Per Share, Basic and Diluted [Abstract] |
EARNINGS (LOSS) PER SHARE | EARNINGS PER SHARE The computation of basic and diluted earnings per common share was as follows (in millions, except per share data):
| Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  |
| 2020 |  | 2019 |  | 2020 |  | 2019
Amounts attributable to Quest Diagnostics’ common stockholders: |  |  |  |  |  |  |
Income from continuing operations | $ | 185 |  |  | $ | 206 |  |  | $ | 284 |  |  | $ | 370 |
Income from discontinued operations, net of taxes | — |  |  | 20 |  |  | — |  |  | 20 |
Net income attributable to Quest Diagnostics’ common stockholders | $ | 185 |  |  | $ | 226 |  |  | $ | 284 |  |  | $ | 390 |
Income from continuing operations | $ | 185 |  |  | $ | 206 |  |  | $ | 284 |  |  | $ | 370 |
Less: Earnings allocated to participating securities | 1 |  |  | — |  |  | 1 |  |  | 1 |
Earnings available to Quest Diagnostics’ common stockholders – basic and diluted | $ | 184 |  |  | $ | 206 |  |  | $ | 283 |  |  | $ | 369 |
Weighted average common shares outstanding – basic | 134 |  |  | 135 |  |  | 134 |  |  | 134 |
Effect of dilutive securities: |  |  |  |  |  |  |
Stock options and performance share units | 2 |  |  | 1 |  |  | 1 |  |  | 2 |
Weighted average common shares outstanding – diluted | 136 |  |  | 136 |  |  | 135 |  |  | 136 |
Earnings per share attributable to Quest Diagnostics’ common stockholders - basic: |  |  |  |  |  |  |
Income from continuing operations | $ | 1.38 |  |  | $ | 1.52 |  |  | $ | 2.12 |  |  | $ | 2.74 |
Income from discontinued operations | — |  |  | 0.15 |  |  | — |  |  | 0.15 |
Net income | $ | 1.38 |  |  | $ | 1.67 |  |  | $ | 2.12 |  |  | $ | 2.89 |
Earnings per share attributable to Quest Diagnostics’ common stockholders – diluted: |  |  |  |  |  |  |
Income from continuing operations | $ | 1.36 |  |  | $ | 1.51 |  |  | $ | 2.09 |  |  | $ | 2.71 |
Income from discontinued operations | — |  |  | 0.15 |  |  | — |  |  | 0.15 |
Net income | $ | 1.36 |  |  | $ | 1.66 |  |  | $ | 2.09 |  |  | $ | 2.86 |
The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect:
| Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  |
| 2020 |  | 2019 |  | 2020 |  | 2019
Stock options | 1 |  |  | 5 |  |  | 2 |  |  | 5 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareBasicAndDilutedAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration